Hepatic targeting of the centrally active cannabinoid 1 receptor (CB<sub>1</sub>R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.

Congruently with the metabolic efficacy of Rimo-NPs, the levels of rimonabant measured 18 h following the last injection of the novel formulation, in comparison to free rimonabant treatment, to HFD-fed mice were significantly higher in liver, kidney, spleen, and blood (with a similar trend found in fat and lungs, which did not reach statistical significance).

also in 111,027 other papers